It's likely that most major health insurers will participate in the insurance exchanges that must be up and running in each state by 2014, according to experts.
NATIONAL REPORTS-It's likely that most major health insurers will participate in the insurance exchanges that must be up and running in each state by 2014 under the Patient Protection and Affordable Care Act (PPACA), experts predict. And most states are likely to set up their own exchanges rather than let the federal government do it.
The exchanges and new insurance rules could foster greater competition and force insurers to operate more efficiently and transparently.
"I believe larger insurers are going to need to be part of the exchanges from a sheer volume perspective," says Maureen Fahey, the national healthcare reform leader for KPMG. "They'll have to balance a lower-margin, higher-volume book of business that's consumer driven. It's a new paradigm."
"We want to make sure we offer opportunities for consumers to continue to purchase the kind of plans they want to buy today," says Donna Zimmerman, senior vice president for government and community relations at HealthPartners, a not-for-profit health plan and health system based in Bloomington, Minn. "As the government sets up the exchanges, it should think about mechanisms to allow those plans to continue to be sold."
The state-based American Health Benefit Exchanges and Small Business Health Options Program Exchanges are central features of PPACA. Every state, or group of states, must offer an exchange so individuals and small businesses of up to 100 employees can select from an array of plans. Lower- and middle-income individuals and families will receive a subsidy to buy coverage through the exchanges. Larger businesses will be able to buy through the exchanges beginning in 2017.
The federal Office of Personnel Management (OPM) must contract with insurers to offer at least two multi-state plans in each exchange, one of which must be not-for-profit. Federal grants will be available to start not-for-profit consumer cooperative plans, which will qualify to market in the exchanges.
Requiring insurers to sell the same standard packages both inside and outside the exchanges lessens the incentive for insurers to sell solely outside the exchanges, says Sara Collins, vice president of the affordable health insurance initiative at the Commonwealth Fund in New York. They won't be able to sell leaner packages to attract younger, healthier customers.
Except for grandfathered plans, products sold both inside and outside the exchanges must conform to four standard benefit designs with different cost-sharing levels; a separate catastrophic package will be available to people aged 30 and under.
Walton Francis, principal author of Checkbook's Guide to Health Plans for Federal Employees, which helps federal workers navigate the Federal Employees Health Benefit Program (FEHBP), says launching the new exchanges by 2014 is entirely doable. States can follow the existing exchange models of the FEHBP, Massachusetts Health Connector, Medicare Advantage and Medicare Part D. He worries, though, that the standard benefit packages required by the new exchanges will be too rich-and expensive.
"The imperative will be to cover more and keep copayments and coinsurance low," he says.
Francis also is concerned about whether insurers will see the exchange risk pools as broad and viable, allowing them to set their premiums appropriately. He cites the Massachusetts experience, where some people have defied the mandate and bought coverage only after getting sick.
"If plans think they'll be forced to operate at a loss, they won't bid, or they'll pull out," he says.
That scenario could happen, he says, should the courts strike down the reform law's mandate mechanism as unconstitutional.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More